Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
Donald Trump’s warnings on drug prices and the tougher stance being taken by governments in Japan and Europe on paying for medicines make this a worrying time for pharma companies, as they nervously keep an eye on leaders’ pledges, policy changes and payer decisions in these mature markets. 30 January 2017
French pharma major Sanofi today announced the appointment of Kathleen Tregoning as a new member of the executive committee, effective February 27, 2017. 30 January 2017
The pharmaceutical sector in India is set to gain rather than be impacted with the new US President Donald Trump's decision to reduce drug prices, given that the country's generic medicines are already affordable. 30 January 2017
US biotech firm Juno Therapeutics has appointed Corsee Sanders as executive vice president and head of development operations, effective immediately. 29 January 2017
On January 26, 2017, Dr Arie Belldegrun resigned as a member of the board of directors of Teva Pharmaceutical Industries, according to a company regulatory filing. 27 January 2017
Russia’s leading biotech firm Biocad is finishing clinical trials of a new anti-cancer drug that will soon appear in the Russian market and will be able to compete with imported analogues. 25 January 2017
Rothschild Europe, a group affiliated with Rothschild family, has called on the Russian government, as well as Andrei Belousov, Russia’s Presidential Aide, to provide support and assistance to the Russian nano and pharmaceutical producer Rusnano and the US drug giant Pfizer in their development in the Russian pharmaceutical market. 25 January 2017
EMD Serono, the biopharmaceutical business of German pharma major Merck KGaA in the USA and Canada, has announced that Richard Smith has been appointed its head of US fertility and endocrinology. 25 January 2017
Integrated delivery networks (IDNs) are growing in importance for pharmaceutical manufacturers as they now represent the majority of the healthcare spend in the USA, writes Theresa Greco, vice president, life sciences, health care, LexisNexis Risk Solutions, in a weekly expert view piece. 25 January 2017
Emily Walsh from the Mesothelioma Cancer Alliance looks at the progress made in the first year of the Cancer Moonshot and considers what lies ahead for the program. 24 January 2017
Monoclonal antibody specialist Kymab has appointed Arndt Schottelius as its first executive vice president of research and development (R&D). 23 January 2017
Dompé chief executive Eugenio Aringhieri is realizing an ambitious plan to transform the privately owned, fully integrated company into an innovative and truly global biotech leader, the first of its kind in Italy. 23 January 2017
Biogen’s $1.25 billion agreement to license Forward Pharma’s intellectual property was a clear boon for the Copenhagen, Denmark-based company, whose shares rose a stunning 55% in morning trade on Tuesday. 22 January 2017
Shanghai Fosun Pharmaceutical and the USA’s Kite Pharma unveiled their plan for the joint venture they are about to establish at a press meeting on Monday in Shanghai, where the JV will be located. 19 January 2017
In an expert view piece, Dr Oded Ben-Joseph and Dr Shawn Manning, from investment bank Outcome Capital, advise on how life sciences companies can curtail risk by allocating time and money in a capital-efficient manner. 19 January 2017
A major change at the top of GlaxoSmithKline’s pharmaceutical business has been announced as part of what has been described as ‘succession processes’ at the company. 19 January 2017
Dr Sam Samaratunga, a GP and life sciences lawyer with Keystone Law, looks at the proposed changes to arrangements for evaluating and funding drugs and other health technologies appraised through NICE’s Technology Appraisal (TA) and Highly Specialized Technologies (HST) programs. 17 January 2017
Given that it is best known for its aesthetic potential in reducing facial wrinkles, few people will know that Botox (onabotulinumtoxinA) has as many as 11 separate therapeutic indications, treating conditions ranging from overactive bladder to chronic migraines. 16 January 2017